Ultragenyx Pharmaceutical Inc.
RARE
Revenue
147.03M
▲38.19M▲35.09%
3 Months ChangeAssets
1.62B
▲311.36M▲23.82%
3 Months ChangeLiabilities
1.19B
▲19.20M▲1.65%
3 Months ChangeFree Cash Flow
-193.94M
▼-12.04M▼-6.62%
12 Months ChangeRevenue/Cost Of Revenue
Revenue
Cost Of Revenue
Loading...
| Date | Revenue | Cost Of Revenue |
|---|---|---|
Net Profit/Loss
Net Profit/Loss
Baseline
Loading...
| Date | Net Profit/Loss |
|---|---|
Assets/Liabilities
Assets
Liabilities
Loading...
| Date | Assets | Liabilities |
|---|---|---|
Cash Flows
Operating (Cash Flow)
Investing (Cash Flow)
Financing (Cash Flow)
Free Cash Flow
Loading...
| Date | Operating (Cash Flow) | Investing (Cash Flow) | Financing (Cash Flow) | Free Cash Flow |
|---|---|---|---|---|
EPS
EPS (Diluted)
Loading...
| Date | EPS | EPS (Diluted) |
|---|---|---|
Outstanding Shares
Loading...
| Date | Outstanding Shares |
|---|---|
Recent 8-K/10-Q Filings
2024-10-07
Form 8-K
ID: 0000950170-24-113085
2024-10-03
Form 8-K
ID: 0000950170-24-112402
2024-08-02
Form 10-Q
ID: 0000950170-24-089488
2024-08-01
Form 8-K
ID: 0000950170-24-089263
2024-07-17
Form 8-K
ID: 0000950170-24-084254
2024-06-21
Form 8-K
ID: 0000950170-24-076222
2024-06-17
Form 8-K
ID: 0001193125-24-162003
2024-06-12
Form 8-K
ID: 0000950170-24-072414
2024-06-12
Form 8-K
ID: 0000950170-24-072119
2024-05-30
Form 8-K
ID: 0000950170-24-066553